Skip to content

Author

L. S. Zemlyanushin

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Post-registration experience with divosilimab in patients with secondary progressive multiple sclerosis with recurrence

Introduction . Therapy aimed at eliminating CD20-positive B cells is considered one of the most significant advances in the treatment of multiple sclerosis. Divozilimab is a humanized anti-CD20 monoclonal antibody lacking fucose in its Fc fragment, which enhances its effector properties. Aim . Тo analyze the e...

A. A. Sokolova, L. S. Zemlyanushin, L. Anishchenko et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.